Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Covid-19 prevention for high-risk individuals

Covid-19 prevention for high-risk individuals
Share on FacebookShare on Twitter

A monoclonal antibody combination, was launched on Jan 6 in the country’s private hospitals for the prevention of Covid-19 in high-risk individuals. It was developed by AstraZeneca’s Evusheld (tixagevimab and cilgavimab.

The National Pharmaceutical Regulatory Agency (NPRA) had granted conditional registration for Evusheld in May 2022 for the pre-exposure prophylaxis (prevention) of Covid-19 in adults and adolescents aged 12 years and older weighing at least 40kg who are unlikely to mount an adequate immune response to Covid-19 vaccination, or for whom Covid-19 vaccination is not recommended.

Evusheld’s introduction to Malaysia’s private market means that the most vulnerable individuals, including immunocompromised patients with underlying health conditions, high-risk individuals and those unable to be vaccinated, can now benefit from an additional prevention option by paying for it through private hospitals.

Dr. Sanjeev Panchal, Country President, AstraZeneca Malaysia speaking at the media launch of monoclonal antibodies.

Dr Sanjeev Panchal, Country President, AstraZeneca Malaysia, said: “Evusheld is an option for high-risk patients to prevent Covid-19 alongside vaccination. While vaccines continue to remain an important tool in the arsenal of protection against the virus, there are some vulnerable populations who are unable to mount an adequate protection from the vaccine alone and some of whom Covid-19 vaccination is not recommended.

“The conditional approval and availability of Evusheld in Malaysia represents an important milestone in our ongoing efforts to contribute towards public health as the country transitions to endemicity and protect high-risk individuals against Covid-19.”

Evusheld is a combination of two monoclonal antibodies (mAbs), tixagevimab and cilgavimab, administered as two intramuscular injections. Unlike a vaccine, which takes time to train the body’s immune system to respond to a virus, antibodies like Evusheld mimic the body’s natural immune response to immediately identify and attack the virus.

The antibodies work by binding to the spike protein of the SARS-CoV-2 virus at two different sites. By attaching to the spike protein, the medicine is expected to stop the virus from entering the body’s cells and causing infection.

Results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial published in The New England Journal of Medicine showed that Evusheld reduced the risk of developing symptomatic Covid-19 by 77 per cent in the primary analysis, and by 83 per cent in the six-month follow-up analysis, compared to placebos. – The Health

Tags: AstraZenecaCovid-19EvusheldLocal Newsmonoclonal antibody combinationNational Pharmaceutical Regulatory AgencyThe Health 2023The Health Jan/Feb 2023theHealth
Previous Post

Duopharma scores a first with halal-certified cancer treatment

Next Post

Board appointments at Hextar Healthcare

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • Healthcare firms’ security gaps
    September 3, 2021
    A new report on data risk in healthcare, pharmaceuticals and biotech has found […]
  • Grand opening ceremony
    November 29, 2021
    BY FATIHAH MANAF SPYGENE LABORATORIES Sdn Bhd marked its official launch on Nov […]
  • Obligatory to take the vaccine
    September 3, 2021
    The Covid-19 vaccination impact is not limited to the taker only but also […]
  • Information, misinformation and disinformation
    April 28, 2022
    The public has valid questions and sound ideas on the Covid-19 situation that […]
  • What is Myopia?
    October 6, 2021
    Myopia is the medical term for nearsightedness, which is a vision condition […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist